The accolade follows Ivim’s recent placement as the 38th fastest-growing company on the 2026 Inc. 5000 list. While industry analysts evaluated 20 different platforms using over 14,000 data points—focusing heavily on clinical support and screening rigor—the company maintains that its most critical performance metric remains the 4.9-star average rating garnered from its own patient base on Trustpilot.

Anthony Kantor, co-founder and CEO, characterized the external recognition as gratifying but secondary to the public feedback loop established by patients. Chief Medical Officer Dr. Jessica Duncan emphasized that the platform’s methodology prioritizes ongoing patient monitoring and plan adjustments over simple prescription fulfillment. This clinical approach was recently reinforced by two peer-reviewed studies published in Obesity Pillars, which analyzed the outcomes of more than 2,000 patients treated under the company's care protocol.